NCT00488527已完成4 期
Multicentric, Open Label Clinical Trial. Use of Optimal Method to Initiate and Maintain Lantus Therapy (Insulin Glargine) in Combination With Hypoglycemic Agents, Assessing the Resulting Metabolic Control and the Safety in T2 Diabetes Mellitus Patients.
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 371
- 试验地点
- 1
- 主要终点
- Change in the initial vs. final values of HbA1c
研究概览
简要总结
To evaluate the efficiency of Lantus plus combined oral hypoglycaemic agents in terms of respondents percentage. The respondent is defined as the person achieving a value in the final determination of HbA1c < 7% as its absolute value and/or a decreasing in the final value of HbA1c of more than 12% compared with the initial value (final HbA1c vs. initial HbA1c).
Describe the glycemia levels and body weight change in the two response groups, (respondents and non-respondents).
Describe the adverse events Evaluate the safety of using the medication according to the incidence and relevance of the hypoglycemia events, (symptomatic, diurnal, nocturnal, severe).
Estimate the intra-patient variability of the fasting glycemia
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with type 2 diabetes mellitus receiving antidiabetic treatment (1 or 2 oral agents) during more than 6 months, who need a prolonged action basal insulin to control hyperglycemia
- •Glycosylated hemoglobin > 8,0% and < 10 %
- •Body mass index (BMI) < 40 kg/m2
- •Voluntary acceptation of the treatment and capability to self inject the insulin glargine
- •Capability and desire to carry out self-determination of glycemia levels using glucometers
排除标准
- •Renal function disorder, revealed by a serum creatinine > 177 µmol/l (> 2,0 mg/dl) in Visit 1 or currently undergoing kidney dialysis
- •Acute metabolic acidosis (> 1 episode during the last year) or chronic, including diabetic ketoacidosis
- •Clinical evidence of an active liver disease or serum ALT/AST >2.5 times the upper normality limit
- •A history of unnoticed hypoglycemia
- •Surgical treatment for diabetic retinopathy, (laser photocoagulation or a vitrectomy), during the three months prior to joining the trial, or patient that has needed treatment within three months of entering the trial
- •Pregnancy or breast feeding
- •Not using an adequate birth control method, (only for potentially fertile females) : for example, the use of systemic hormones, (pills or birth control implants), intrauterine devices or a barrier method, (diaphragm with intra-vaginal spermicides, male or female preservative)
- •Known hypersensitivity to insulin glargine or any of its excipients
- •Malignant process, except for basal carcinoma cells during the last five years
- •More than two weeks of continuous treatment with systemic glucocorticoids in the last 6 months
- •Concomitant treatment with non-cardio selective beta blockers
- •Known supra-renal failure
- •Known hemoglobinopathy or anemia, uncontrolled or unstable
- •A psychiatric disturbance which prevents the patient from understanding the nature, objective and possible consequences of the trial
- •A history of drug or alcohol abuse in the last two years or any current addiction
- •Current use of insulin glargine
- •Any clinically relevant, cardiovascular, hepatic, neurological, endocrinal or systemic major disease, or any other type, which may hinder the development of the protocol or the interpretation of the results of the trial
- •Known existence of GAD (glutamic acid decarboxylase) antibodies
- •Type 1 diabetes mellitus, according to its definition by the WHO
- •The use of a drug being researched other than insulin during six months prior to joining the trial or the use of an insulin under study during four weeks before entering the trial
- •A history of severe hypoglycemia with repeated blackouts, (more than 1), during the last year
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
研究组 & 干预措施
1
Experimental
干预措施: Insulin glargine (Drug)
结局指标
主要结局
Change in the initial vs. final values of HbA1c
时间窗: 9 months
Number of severe hypoglycemia
时间窗: 9 months
次要结局
- - Change in the fasting glucose values with each visit(9 months)
- - Incidences of symptomatic and asymptomatic nocturnal hypoglycemia - Evaluations of safety with regards to the use of insulin glargine, recording the adverse events, excluding hypoglycemia - Abnormal laboratory results(9 months)
- - Change in body weight initial visit vs. final visit(9 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Glycemic Optimization Treatment StudyDiabetes Mellitus, Type 2NCT00552370Sanofi5,062
已完成
4 期
Insulin Glargine Benefits in Japanese Pts Outside of Japan (US or Brazil)Diabetes MellitusNCT00642915Sanofi100
已完成
2 期
Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist StudyMonogenic DiabetesType 1 DiabetesNCT04409795Joslin Diabetes Center3
已完成
4 期
Effects of Different Early Intensive Therapies on Long-term β-cell FunctionDiabetes Mellitus, Type 2NCT01471808Sun Yat-sen University264
已完成
3 期
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)Type 2 DiabetesChronic Kidney DiseaseNCT01621178Eli Lilly and Company577